Cervella

05/14/2024

According to a recent (11/23) study by Statista of 2074 adults, one in two of Americans experienced stress and/or anxiety in the preceding twelve months. Note that only 22% of respondents have indicated that they have not recently experienced any mental health issues.

Cervella, as an FDA-cleared medical device for treatment of anxiety and insomnia, hopes to address this very concerning statistics by offering a drug-free, non-habit-forming, way to combat the two most prevalent disorders. Our patient feedback data confirm this: over 92% of patients suffering from anxiety, depression, or insomnia report that the Cervella device is beneficial in reducing the symptoms without side-effects which often accompany drug-based solutions.

By incorporating the treatment electrodes into the Bluetooth-enabled, noise-cancelling stereo headphones, patients can receive the treatment work, study, or play. This, in turn, improves compliance and increases chances of successful outcomes.

12/06/2022

Check out more reviews at www.cervella.us

11/29/2022

11/08/2022

Cervella is an FDA-cleared, award-winning medical device for non-drug medical treatment of anxiety and insomnia. Check us out at www.cervella.us

11/02/2022

Are you thinking about Cervella but having difficulty finding a licensed healthcare provider in order to obtain the Medical Device Authorization? If so, we have good news for you. We now offer a medical device authorization screening through an independent licensed healthcare provider at no extra cost to you!

10/27/2022

FALL SPECIAL: Take advantage of $200 OFF limited-time offer and our 30-DAY risk-free trial. No coupon required, price will be discounted automatically.

10/25/2022

Fall Special: Take advantage of our $200 off offer and 30-day trial. No coupon required.

04/22/2022

Interview with our CEO on Into Tomorrow with Dave Graveline

INNOVATIVE NEUROLOGICAL DEVICES has developed Cervella, an FDA-approved medical device for non-drug treatment of anxiety and insomnia. In this segment, Dave ...

04/11/2022

Cervella News, Users Tips, and More! - Spring 2022 -

We also wanted to take an opportunity to answer some of the Frequently Asked Questions that we have received from our customers and healthcare providers which may be of help to you.

04/08/2022

Just complete a short (HIPAA-compliant) questionnaire during checkout and an independent, licensed healthcare provider will review your order at no additional cost.

10/14/2021

Cervella User News, Tips, and More! Fall 2021 -

What changed? We eliminated the need for the user to register and log into their user account. Instead, the treatment data is stored on the user’s smart device and now the user can import/export the treatment history via CSV file. This can be useful when sharing treatment dates with patient’s tr...

08/18/2021

Interesting article showcasing various approaches to treatment of Anxiety, Insomnia, and Depression. It is important to underscore that currently only Cranial Electrical Stimulation (CES) is FDA-cleared as the technology for treatment of the disorders.

Depression and anxiety are still treated mostly using pharmaceuticals and therapy techniques, but several medical devices exist for tackling the conditions

08/04/2021

We are offering $200 OFF the price of the Cervella system https://cervella.us/shop/ for the balance of August. Just enter cervellacv19 at check-out.

05/24/2021

Cervella Anxiety Long-Term Patient Study Results

In 2020, our team completed a clinical evaluation of 240 randomly-selected Cervella patients (57% female and 43% male) who were prescribed the Cervella medical device for treatment of anxiety, insomnia, depression, or combination of these three disorders. Each patient was evaluated before starting treatment and after approximately 8 weeks / 60 days from start of treatment. Patients were instructed to use the device daily for 30 minutes at the default 100Hz setting. Patients were free to choose the best time of day to use the treatment and the intensity of the treatment was also controlled by patient (since it varies from patient to patient) but all patients were instructed to only adjust the treatment intensity to the level where the “tingling” sensation is barely perceptible.

This graph shows the reduction of median anxiety level, as measured by GAD-7). The median anxiety level before treatment was 16 which is in the 16 – “Severe” anxiety category. Post treatment (approx. 8 weeks) the median anxiety level among patent population was reported as 9 – “Mild”, a reduction of 7 points on the GAD-7 scale.